Retatrutide is intended for the treatment of patients with obesity. Credit: Jelena Stanojkovic/Shutterstock.com.

Eli Lilly and Company has reported that its Phase II clinical trial of retatrutide for the treatment of obesity has met its primary endpoint and demonstrated a mean weight reduction of up to 17.5% at 24 weeks.

The placebo-controlled, randomised, double-blind study in the US is designed to assess the safety, tolerability, and efficacy of the investigational molecule retatrutide in obese populations with weight-related conditions except type 2 diabetes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

A total of 338 participants were randomised in a 2:1:1:1:1:2:2 ratio to receive subcutaneous doses of retatrutide comprising 1mg, 4mg (with an initial dose of 2mg), and 4mg (with an initial dose of 4mg) once weekly for 48 weeks.

Dosages of 8mg (with an initial dose of 2mg), 8mg (with an initial dose of 4mg), 12mg (with an initial dose of 2mg) or placebo were also given to the participants.

The therapy demonstrated a mean weight reduction of up to 24.2% at the end of the 48-week treatment duration, in a secondary endpoint.

The retatrutide group also showed improvements in LDL-cholesterol, triglycerides, fasting glucose and insulin levels, total cholesterol, HbA1c, as well as systolic and diastolic blood pressure, measured as exploratory endpoints.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Lilly chief scientific and medical officer, and Lilly Research Laboratories president Dan Skovronsky said: “We believe that combining glucagon receptor agonism with GIP and GLP-1 receptor agonism may be one of the reasons retatrutide showed this level of weight reduction.

“These phase II data have given us the confidence to further explore the potential of retatrutide in Phase III trials that will look beyond weight reduction and focus on treating obesity and its complications comprehensively.”

Lilly is also assessing the safety and efficacy of retatrutide for knee osteoarthritis, chronic weight management, and obstructive sleep apnoea in obese people, as part of its TRIUMPH Phase III development programme.